Welcome!

News Feed Item

Stammering Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stammering Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280948/Stammering-Global-Clinical-Trials-Review-H2-2014.html

Stammering Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Stammering Global Clinical Trials Review, H2, 2014" provides data on the Stammering clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Stammering. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Stammering. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Stammering 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Stammering to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Stammering to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Stammering 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Clinical Trial Profiles 25
Clinical Trial Overview of Top Companies 25
Endo International plc 25
Clinical Trial Overview of Endo International plc 25
Clinical Trial Overview of Top Institutes / Government 26
National Institute on Deafness and Other Communication Disorders 26
Clinical Trial Overview of National Institute on Deafness and Other Communication Disorders 26
National Institute of Neurological Disorders and Stroke 27
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 27
The University of Sydney 28
Clinical Trial Overview of The University of Sydney 28
Tbilisi State Medical University 29
Clinical Trial Overview of Tbilisi State Medical University 29
Universidade Federal de Minas Gerais 30
Clinical Trial Overview of Universidade Federal de Minas Gerais 30
Pharmacology Research Institute 31
Clinical Trial Overview of Pharmacology Research Institute 31
The Newcastle upon Tyne Hospitals NHS Foundation Trust 32
Clinical Trial Overview of The Newcastle upon Tyne Hospitals NHS Foundation Trust 32
Universitatsklinikum Munster 33
Clinical Trial Overview of Universitatsklinikum Munster 33
University of California, Irvine 34
Clinical Trial Overview of University of California, Irvine 34
Five Key Clinical Profiles 35
Appendix 50
Abbreviations 50
Definitions 50
Research Methodology 51
Secondary Research 51
About GlobalData 52
Contact Us 52
Disclaimer 52
Source 52

List of Tables

Stammering Therapeutics, Global, Clinical Trials by Region, 2014* 6
Stammering Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Stammering Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Stammering Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Stammering Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Stammering Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Stammering Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Stammering to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Stammering Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Stammering Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Stammering to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Stammering Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Stammering Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Stammering Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Stammering Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Stammering Therapeutics, Global, Suspended Clinical Trials, 2014* 21
Stammering Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Stammering Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Stammering Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Endo International plc, 2014* 25
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute on Deafness and Other Communication Disorders, 2014* 26
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 27
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2014* 28
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Tbilisi State Medical University, 2014* 29
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Universidade Federal de Minas Gerais, 2014* 30
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacology Research Institute, 2014* 31
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by The Newcastle upon Tyne Hospitals NHS Foundation Trust, 2014* 32
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitatsklinikum Munster, 2014* 33
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2014* 34

List of Figures

Stammering Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Stammering Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Stammering Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Stammering Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 10
Stammering Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Stammering to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Stammering Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Stammering Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Stammering to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Stammering Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Stammering Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Stammering Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Stammering Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Stammering Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
GlobalData Methodology 51

To order this report: Stammering Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280948/Stammering-Global-Clinical-Trials-Review-H2-2014.html

_________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to o...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
SYS-CON Events announced today that Hitachi Data Systems, a wholly owned subsidiary of Hitachi LTD., will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City. Hitachi Data Systems (HDS) will be featuring the Hitachi Content Platform (HCP) portfolio. This is the industry’s only offering that allows organizations to bring together object storage, file sync and share, cloud storage gateways, and sophisticated search an...
Developers want to create better apps faster. Static clouds are giving way to scalable systems, with dynamic resource allocation and application monitoring. You won't hear that chant from users on any picket line, but helping developers to create better apps faster is the mission of Lee Atchison, principal cloud architect and advocate at New Relic Inc., based in San Francisco. His singular job is to understand and drive the industry in the areas of cloud architecture, microservices, scalability ...
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across supply chain networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost and time for product recall as well as advance trade. Are you curious about Blockchain and how it can provide you with new opportunities for innovation and growth? In her session at 20th Cloud Exp...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software in the hope of capturing value in IoT. Although IoT is relatively new in the market, it has already gone through many promotional terms such as IoE, IoX, SDX, Edge/Fog, Mist Compute, etc. Ultimately, irrespective of the name, it is about deriving value from independent software assets participating in an ecosystem as one comprehensive solution.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.